Source-grounded facts extracted from Sigyn Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sigyn Therapeutics, Inc. issued convertible note to Lambda Venture Partners, LLC for $27,777.77 principal amount, $21,500.00 net proceeds.
“On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77, which resulted in net proceeds of $21,500.00 to the Company after the payment of related legal fees.”
Sigyn Therapeutics, Inc. issued convertible note to Osher Capital Partners, LLC for $22,222.22 principal amount, $20,000.00 gross proceeds.
“On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22, which resulted in gross proceeds of $20,000.00 to the Company.”
Sigyn Therapeutics, Inc. issued convertible note to Brio Capital Master Fund, Ltd for $22,222.22 principal amount, $20,000.00 gross proceeds.
“On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22, which resulted in gross proceeds of $20,000.00 to the Company.”
Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Lambda Venture Partners, LLC valued at $27,777.77 (effective 2026-02-06).
“On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77”
Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Osher Capital Partners, LLC valued at $22,222.22 (effective 2026-02-12).
“On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22”
Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Brio Capital Master Fund, Ltd valued at $22,222.22 (effective 2026-02-12).
“On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22”
James Joyce was appointed as interim Chief Financial Officer at Sigyn Therapeutics, Inc..
“Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.”
Gerald DeCiccio retired as Chief Financial Officer at Sigyn Therapeutics, Inc..
“On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.”
Michael Ryan was appointed as Director at Sigyn Therapeutics, Inc..
“On January 11, 2025, our Board of Directors appointed Michael Ryan to our Board of Directors.”
Sigyn Therapeutics, Inc.: Amended authorized common stock to 100,000,000 shares (effective 2024-12-30).
“On December 30, 2024, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the State of Delaware, which went effective immediately upon filing. The Certificate of Amendment decreased our authorized common stock to One Hundred Million (100,000,000) shares, par value $0.0001.”
Sigyn Therapeutics, Inc. amended Debentures with Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC valued at $110,000 and $275,000 (effective 2024-04-10).
“Brio and Osher agreed to amend an additional $110,000 and $275,000, respectively, of Debentures to extend the maturity dates of such Debentures to March 31, 2025 in return for an increase in principal amount of such Debentures to $125,000 and $316,350”
Sigyn Therapeutics, Inc.: Filing of Certificate of Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-40 reverse stock split, effective January 31, 2024 (effective 2024-01-31).
“On January 23, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on January 31, 2024 with a ratio of 1-for-40 (the “Reverse Split”).”
Sigyn Therapeutics, Inc. entered into Share Surrender Agreement with Craig Roberts (effective 2024-01-09).
“On January 9, 2024, Sigyn Therapeutics, Inc. (the “Company”) entered into a Share Surrender Agreement with Craig Roberts, Chief Technical Officer and member of the board of directors of the Company (the “Shareholder”), whereas the parties agreed that 2,564,000 shares of common stock, par value $0.001, shall be surrendered by the Shareholder to the Company for cancellation and shall subsequently not be held as treasury shares or represent any claim against the Company whatsoever, effective immediately.”
Jerry DeCiccio was appointed as Chief Financial Officer at Sigyn Therapeutics, Inc..
“The Company has appointed Jerry DeCiccio to serve as the Chief Financial Officer of the Company, effective immediately.”
Jeremy Ferrell was removed as Chief Financial Officer at Sigyn Therapeutics, Inc..
“the Company removed Jeremy Ferrell from his position as CFO of the Company, effective immediately.”
Sigyn Therapeutics, Inc. amended Amendment Agreement with certain accredited investors valued at $2,161,316 principal amount (effective 2023-09-14).
“On September 14, 2023, the Company entered into Amendment Agreements with $2,161,316 principal amount of these notes to extend the maturity date to August 30, 2024.”
Sigyn Therapeutics, Inc.: Filed a certificate of designation establishing the rights, preferences, privileges and restrictions of a series of Preferred Stock (effective 2023-06-30).
“On June 30, 2023, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of Preferred Stock.”
Sigyn Therapeutics, Inc. entered into Warrant Exchange Agreements with certain holders of warrants issued between October 20, 2020 and February 9, 2023 (effective 2023-06-30).
“On June 30, 2023, Sigyn Therapeutics, Inc. (the “Company”) entered into Warrant Exchange Agreements with certain holders of warrants issued between October 20, 2020 and February 9, 2023 (the “Warrants”) to exchange the Warrants for newly issued shares of Common Stock and Series A Preferred Stock”
Christopher Wetzel was appointed as Director at Sigyn Therapeutics, Inc..
“The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.”
Richa Nand was appointed as Director at Sigyn Therapeutics, Inc..
“The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.”
Jim Dorst was appointed as Director at Sigyn Therapeutics, Inc..
“The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.”
Jeremy Ferrell was appointed as Chief Financial Officer at Sigyn Therapeutics, Inc..
“The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March 9, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.